Trial reportScientific reports2025
Comparison of rebamipide and tegoprazan combination therapy and tegoprazan monotherapy for ESD induced gastric ulcers a randomized multicenter study.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Currently, no consensus exists on optimal treatment for post-endoscopic submucosal dissection (ESD) gastric ulcer. This study aims to compare rebamipide and tegoprazan combination therapy with tegoprazan monotherapy for post-ESD ulcer healing. Between May 2022 and September 2023, 140 patients (141 lesions) who underwent ESD for gastric epithelial neoplasms at five tertiary hospitals were randomly assigned to tegoprazan monotherapy or combination therapy groups. The size, stage and healing quality of the post-ESD ulcers were assessed at weeks 4 and 8. Modified intention-to-treat (mITT) and per-protocol analyses included 132 and 121 lesions, respectively. The ulcer healing rate at week 4 was significantly higher in the combination therapy group than in the tegoprazan monotherapy group (96.4% vs. 93.6%, P = 0.02 in mITT). Combination therapy significantly predicted higher-than-average ulcer healing at week 4 (odds ratio 2.28, 95% confidence interval 1.04-5.02, P = 0.04). The proportion of flat ulcer scar at week 8 was significantly higher in the combination group than in the tegoprazan monotherapy group (73.8% vs. 48.4%, P = 0.007). Combination treatment with rebamipide and tegoprazan led to faster ulcer healing and the development of high-quality post-ESD scars compared to tegoprazan monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.